Brief: Novartis Provides Update On Delpacibart Etedesiran (Del-Desiran) Phase Iii Harbor Study
08/09/2026 06:05
BRIEF-Novartis Provides Update On Delpacibart Etedesiran (Del-Desiran) Phase Iii Harbor Study Sept 8 (Reuters) - NOVARTIS AG NOVN.S:
PROVIDES UPDATE ON DELPACIBART ETEDESIRAN (DEL-DESIRAN) PHASE III HARBOR STUDY FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (DM1)
HARBOR PHASE III STUDY DID NOT MEET PRIMARY ENDPOINT IN DM1
DEL-DESIRAN SHOWED EVIDENCE OF CLINICAL ACTIVITY IN SECONDARY ENDPOINTS
MAINTAINS 5-6% FIVE-YEAR SALES CAGR GUIDANCE FOR 2025-2030
FDA GRANTS PRIORITY REVIEW FOR DELPACIBART ZOTADIRSEN IN DMD44
Source text: ID:nGNE9BzK3V
Further company coverage: NOVN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))
Recent news on Novartis AG
See all newsNovartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx